Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2017 | The impact of antiemetics

Matti Aapro, MD, from the Multidisciplinary Oncology Institute, Genolier, Switzerland, discusses the development of new antiemetics at the European Society for Medical Oncology (ESMO) 2017 in Madrid, Spain. New antiemetics have been developed, for example, NEPA, a combination of an NK receptor antagonist and palonosetron. The development of these will have a big impact on the quality of life of patients.